American Cancer Society’s Newly Formed Philanthropic Impact Fund Makes First Investment

ATLANTA & FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. and American Cancer Society’s newly formed philanthropic fund, BrightEdge, today announced that BrightEdge participated in a recent convertible note financing of Castle Biosciences of approximately $12 million. The investment is BrightEdge’s first since its formation to invest in companies developing promising cancer-related therapeutics, diagnostics, devices and technologies. Castle Biosciences is a commercial stage dermat

Full Story →